Regenxbio RGNX
Valuation
Multiples measured against the stock's own five-year history
Around its usual level · 50th percentile, 5-year average 0.2x
Near the top of its 5-year range · 81st percentile, 5-year average 3.4x
#3931 of 5329 stocks by PB (1 = cheapest)
Below its usual level · 37th percentile, 5-year average 5.4x
#3325 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.41 | – | 3.41 | 81% (pricier than usual) | #3931 of 5329 (1 = cheapest) |
| PE | -2.39 | -1.94 | 0.16 | 50% (cheaper than usual) | – |
| PS | 3.28 | 4.92 | 5.41 | 37% (cheaper than usual) | #3325 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on RGNX.
Sign in to join the discussion.